One of the primary reasons influencing the market expansion is the rising prevalence of chronic lifestyle illnesses and infections caused by microbial dysbiosis worldwide. Furthermore, the market growth is being boosted by the growing elderly population, who are more vulnerable to such illnesses. The increased focus on creating human microbiome treatments with improved efficacy can also be credited with the market's expansion. The creation of target-specific microbiome-based treatments is just one of the several developments that are promoting market expansion. The pharmaceutical business is expected to increase significantly, especially in developing nations, along with other factors including intensive research and development (R&D) efforts, and these are all expected to fuel market expansion.
Since financing for research and development and consumer spending on healthcare goods and services are both impacted by recessions, they may also have an effect on the market for human microbiome products. Although businesses and investors may have less money to invest in new technologies and goods during recessions, research and development investment generally declines during these times. Due to this, the market for human microbiome innovation may sluggishly advance, delaying the creation of novel treatments and diagnostics. Recessions can also affect how much the general public spends on healthcare services and goods, including those that are connected to the human microbiome.
Increased Emphasis On Human Microbiome Therapeutics Development To Drive Market Growth
The efficacy of pharmaceuticals is significantly enhanced by the human gut flora. Studies over the years have demonstrated that the proper microbial mix in the human body is helpful for treating a variety of illnesses. This link between particular disease states and bacteria may present new prospects for medication development (or vaccine manufacturers). Microbes are abundant suppliers of enzymes, which makes them useful for a variety of therapeutic purposes, including the search for innovative treatments. To hasten the development of medicinal medications, numerous human microbiome-based product firms receive funding. To promote the clinical development of VE303 for high-risk Clostridioides difficile infection, Vedanta Biosciences (US) obtained funding from the Biomedical Advanced Research and Development Authority (BARDA) in 2020 totaling USD 7.4 million, with the possibility of USD 69.5 million more (CDI). The money will also be utilised to enhance the company's platform and pipeline, including the start of Phase 1b trials for the treatments of chronic hepatitis B and autistic spectrum disorder using the drugs FIN-211 and CP101 (HBV). The human microbiome market is anticipated to grow over the next few years thanks to similar funding and investments that are focused on microbiome research for the development of pharmaceuticals.
High Cost of Human Microbiome to Limit Market Growth
One major problem impeding the expansion of the human microbiome market is the high cost of microbial therapy. A microbial therapy called faecal transplantation can cost a lot more or less depending on how and where it is delivered to the patient. The cost of a faecal microbiota transplant procedure can range from $600-$1,000 depending on the type of procedure, the patient's location, insurance status, and other factors. Hence, it is anticipated that the high price of microbial therapy will restrain the development of the human microbiome market.
Based on product, the human microbiome market is segmented into probiotics, prebiotics, diagnostic test, drugs and other products. The drugs category dominated the market in 2022. This segment's sizeable contribution may be attributed to a growth in the number of human microbiome-based medicinal products in clinical trials and financing for the development of microbiome-based drugs. A growing number of medicines based on the human microbiome are currently undergoing clinical trials, and funding for their development is rising, which may account for this segment's sizeable market share.
Based on disease, the human microbiome market is segmented into infection diseases, endocrine and metabolic disorders, cancer and other diseases (cardiovascular diseases, neurological disorders, dermatology diseases, immune-modulated disorders, and hematological disorders). The infection diseases category dominated the market in 2022. The need for bacterial-targeted treatment for infectious diseases has been highlighted by the rising awareness of the harmful effects of antibiotic use on natural flora (such as disruptions). The main factors influencing the growth of this market are the rising prevalence of diseases brought on by microbial dysbiosis as a result of antibiotic therapy and the rise in clinical studies for the creation of target-specific microbiome-based therapies.
Based on application, the human microbiome market is segmented into therapeutics and diagnostics. The therapeutics category dominated the market in 2022. Applications for microbiome therapeutics in COVID-19, inflammatory bowel disease (IBD), C. difficile infections, Crohn's disease, and diabetes are numerous. The market segment is expanding as a result of factors like the increased research efforts being made by research facilities and industry participants to identify additional therapeutic uses for the human microbiome. These efforts are also being fueled by the rising number of diseases.
Based on type, the human microbiome market is segmented into FMT, peptide, live biotherapeutic product and others. The live biotherapeutic product category dominated the market in 2022. A class of medicinal drug developed from the human microbiome is known as a live biotherapeutic product (LBP). To maintain, safeguard, or improve the body's natural microbiome, patients are given LBPs, which are live microorganisms. They are intended to treat a range of illnesses and problems, such as metabolic abnormalities, skin diseases, and gastrointestinal issues.
Based on technology, the human microbiome market is segmented into genomics, sequencing, proteomics and metabolomics. The genomics category dominated the market in 2022. The study of the human microbiome relies heavily on genomics, which is also a significant area of research in this field. By identifying and analysing the genetic makeup of the bacteria that make up the microbiome, researchers can learn more about their function, interactions with host cells, and possible therapeutic uses.
North America is projected to hold the largest share of the human microbiome market over the forecast period due to a strong foundation of healthcare facilities, greater investment from large firms in advancing sophisticated technology, speeding up the creation of new drugs, and rising research activity in this field. The market is expanding as a result of rising rates of lifestyle diseases, a focus on human microbiome therapies, and more technological advancements in next-generation sequencing and the human microbiome. On the other hand, the Europe human microbiome market is anticipated to grow significantly because of the market participants' growing R&D activity. For instance, the U.S. Food and Drug Administration (FDA) granted Investigational New Drug (IND) clearance to ENTEROME on March 24, 2021, allowing it to move forward with a Phase 1/2 clinical trial of EO2463, a potential treatment for indolent non-Hodgkin B-cell lymphomas. ENTEROME develops novel drugs based on its unique ability to decode molecular interactions in the gut microbiome impacting human health (iNHL). Further accelerating the market's expansion is the region's rising disease burden.
LIST OF KEY COMPANIES PROFILED:
- ENTEROME (France)
- Yakult (US)
- DuPont (US)
- Metabiomics Corporation (US)
- ViThera Pharmaceuticals, Inc. (US)
- Second Genome Inc. (US)
- MICROBIOME THERAPEUTICS LLC (US)
- Vedanta Biosciences, Inc. (US)
- Osel, Inc. (US)
- Merck Sharp & Dohme Corp (Germany)
- Seres Therapeutics (US)
- Synthetic Biologics, Inc. (US)
- Synlogic (US)
- 4D pharma plc (UK)
- Metabogen AB (Sweden)
- Ritter Pharmaceuticals (US)
- Symberix (US)
- Symbiotix Biotherapies, Inc. (US)
In September 2021, a human gut microbiota assay from PhenoBiome was released today through Genetic Direction, which will perform the assays in a lab that has received CLIA and CAP certification.
REPORT SCOPE AND SEGMENTATION
|Market Size in 2022
|USD 245.1 Billion
|Market Forecast in 2030
|USD 1579.9 Billion
|Compound Annual Growth Rate
|Revenue (USD Million) and Volume (Kilo Tons)
|By Product, By Disease, By Application, By Type, By Technology and By Geography